KR20220141377A - A composition for relieving hangovers containing turmeric and the process for the preparation thereof - Google Patents
A composition for relieving hangovers containing turmeric and the process for the preparation thereof Download PDFInfo
- Publication number
- KR20220141377A KR20220141377A KR1020210047237A KR20210047237A KR20220141377A KR 20220141377 A KR20220141377 A KR 20220141377A KR 1020210047237 A KR1020210047237 A KR 1020210047237A KR 20210047237 A KR20210047237 A KR 20210047237A KR 20220141377 A KR20220141377 A KR 20220141377A
- Authority
- KR
- South Korea
- Prior art keywords
- turmeric
- weight
- hangover
- powder
- relieving
- Prior art date
Links
- 206010019133 Hangover Diseases 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 235000003373 curcuma longa Nutrition 0.000 title claims abstract description 55
- 235000003392 Curcuma domestica Nutrition 0.000 title claims abstract description 54
- 235000013976 turmeric Nutrition 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims description 18
- 230000008569 process Effects 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 6
- 244000008991 Curcuma longa Species 0.000 title 1
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 54
- 239000000843 powder Substances 0.000 claims abstract description 49
- 239000006187 pill Substances 0.000 claims abstract description 42
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 31
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 30
- 238000009472 formulation Methods 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 241000383638 Allium nigrum Species 0.000 claims abstract description 20
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 6
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 21
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 21
- 235000013336 milk Nutrition 0.000 claims description 16
- 239000008267 milk Substances 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 16
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 14
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 14
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 14
- 239000001138 artemisia absinthium Substances 0.000 claims description 14
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 235000015701 Artemisia arbuscula Nutrition 0.000 claims description 9
- 235000002657 Artemisia tridentata Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000004898 kneading Methods 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 2
- 235000009120 camo Nutrition 0.000 claims description 2
- 235000005607 chanvre indien Nutrition 0.000 claims description 2
- 239000011487 hemp Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 35
- 239000004480 active ingredient Substances 0.000 abstract description 26
- 235000010841 Silybum marianum Nutrition 0.000 abstract description 6
- 241000320380 Silybum Species 0.000 abstract description 5
- 239000011230 binding agent Substances 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- -1 color Substances 0.000 abstract description 3
- 239000002075 main ingredient Substances 0.000 abstract description 3
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 2
- 235000010804 Maranta arundinacea Nutrition 0.000 abstract description 2
- 235000012419 Thalia geniculata Nutrition 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 244000010000 Hovenia dulcis Species 0.000 abstract 1
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 244000151018 Maranta arundinacea Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 89
- 235000019441 ethanol Nutrition 0.000 description 68
- 210000004185 liver Anatomy 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 16
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 14
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 14
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 12
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000035622 drinking Effects 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000004148 curcumin Substances 0.000 description 7
- 235000012754 curcumin Nutrition 0.000 description 7
- 229940109262 curcumin Drugs 0.000 description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010019837 Hepatocellular injury Diseases 0.000 description 5
- 241000736075 Schisandra Species 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 231100000234 hepatic damage Toxicity 0.000 description 5
- 230000008818 liver damage Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 240000002234 Allium sativum Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000008184 Piper nigrum Nutrition 0.000 description 4
- 244000203593 Piper nigrum Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 235000013614 black pepper Nutrition 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 235000004611 garlic Nutrition 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 208000007613 Shoulder Pain Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 2
- 235000010081 allicin Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 235000021438 curry Nutrition 0.000 description 2
- 235000019503 curry powder Nutrition 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008789 oxidative DNA damage Effects 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000145580 Thalia geniculata Species 0.000 description 1
- 241000006350 Turraea heterophylla Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000005415 artificial ingredient Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021060 food property Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940029982 garlic powder Drugs 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000005876 negative regulation of fatty acid oxidation Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001060 yellow colorant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 울금을 유효성분으로 포함하는 숙취해소용 환 및 이의 제조방법에 관한 것으로, 보다 구체적으로는 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 혼합물을 유효성분으로 포함하는 것을 특징으로 하는 숙취해소에 있어서 극대화된 시너지 효과를 나타내면서도 기호도가 향상된 숙취해소용 환의 제조방법 및 이에 의해 제조된 환에 관한 것이다.The present invention relates to a hangover relieving pill containing turmeric as an active ingredient and a method for manufacturing the same, and more specifically, to a mixture of turmeric, Heotgae tree fruit, milk seed extract, brown root, black garlic, wormwood, Goji berry and Schisandra schisandra as an active ingredient. It relates to a method for producing a hangover relief ring with improved preference while exhibiting a maximized synergistic effect in relieving a hangover, characterized in that it comprises, and a ring manufactured thereby.
산업발전으로 인한 업무의 복잡성과 다양함으로 인해 회식과 접대가 잦고, 여러 가지 요인에 의한 스트레스가 많은 현대인들에게 음주는 필수적인 것으로 자리잡고 있으며, 그로 인하여 음주기회가 상당히 증가하고 있는 실정이다. Due to the complexity and diversity of work due to industrial development, drinking is becoming essential for modern people who have frequent dinner parties and entertainment, and who are stressed by various factors, and as a result, drinking opportunities are significantly increasing.
한국의 알코올 소비는 세계 최고의 수준이며, 간암이나 간 경변으로 인한 사망이 국민의 주요 사망원인이 되는 등 음주로 인한 사회경제적 및 보건학적 폐해는 엄청나며 이는 증가 추세에 있다. 과다한 알코올 섭취는 신체의 거의 모든 부분에 영향을 미쳐서 간질환, 위염, 췌장염, 고혈압, 중풍, 식도염, 당뇨병 그리고 심장병 등 많은 질환을 일으키는 것으로 보고되고 있다. Alcohol consumption in Korea is at the highest level in the world, and the socioeconomic and health effects of drinking are enormous, and the number of deaths from liver cancer or cirrhosis is the main cause of death. It has been reported that excessive alcohol intake affects almost all parts of the body and causes many diseases such as liver disease, gastritis, pancreatitis, high blood pressure, stroke, esophagitis, diabetes and heart disease.
숙취 현상이란 간세포에 축적된 에틸알콜 및/또는 아세트알데히드 독작용에 의해 발생하는 것으로, 에틸알콜 및/또는 아세트아데히드의 독작용이 장시간 계속되고 결국 신진 대사 등에 장애를 일으켜 전신권태, 피로감, 복부팽만감, 구토 등의 증상을 초래하는 현상을 의미한다. 숙취는 통상 수 시간에서 며칠에 걸쳐서 나타날 수 있다. 주요 증상으로는 두통, 근육통, 메슥거림, 구토, 현기증, 집중력 저하, 구갈, 피로감, 포만감, 과흥분증, 초조 및 우울증상, 발한 등이 있다. 수면 패턴의 변화, 위장관 불쾌증상 등도 수반될 수 있다. 탈력감과 인지 능력의 감소가 알코올에 의한 숙취의 중요한 증상일 수도 있다. The hangover phenomenon is caused by the toxic action of ethyl alcohol and/or acetaldehyde accumulated in the liver cells. It means a phenomenon that causes symptoms such as bloating and vomiting. A hangover can usually occur over a period of several hours to several days. The main symptoms include headache, muscle pain, nausea, vomiting, dizziness, poor concentration, dry mouth, fatigue, satiety, hyperexcitability, agitation and depression, and sweating. Changes in sleep patterns and discomfort in the gastrointestinal tract may also be accompanied. Weakness and decreased cognitive ability may be important symptoms of alcohol-induced hangovers.
숙취해소제는 전술한 알코올 대사특성상 한국을 비롯한 일본, 중국, 대만 등의 동북아시아 국가를 중심으로 시장이 활성화되어 있어 이들 국가에서 다양한 제품 개발이 활발히 진행되고 있다. Due to the characteristics of alcohol metabolism described above, the market for hangover remedies is active mainly in Northeast Asian countries such as Korea, Japan, China, and Taiwan, and various products are being developed actively in these countries.
숙취제거 및 혈중 알코올 농도를 감소시킬 수 있는 제제의 연구가 그동안 활발히 이루어져 왔으나 뚜렷한 성과가 있는 제제는 아직까지 없는 실정이다.Research on drugs that can remove hangovers and reduce blood alcohol concentration have been actively conducted, but there is still no drug with clear results.
술의 주성분인 에탄올(ethanol)은 신체적, 정신적으로 인체에 미치는 효과가 매우 다양하고 광범위하여 그 대사 과정과 독성 발현 특성에 대한 많은 연구가 진행되고 있다. 섭취된 에탄올은 소화관을 통해 흡수되어 섭취 후 20 ~120분 사이에 최고 혈중 농도에 도달한다.Ethanol, the main component of alcohol, has a very diverse and extensive effect on the human body physically and mentally, and many studies are being conducted on its metabolic process and toxic expression characteristics. Ingested ethanol is absorbed through the digestive tract, reaching peak blood levels between 20 and 120 minutes after ingestion.
흡수된 에탄올은 간을 비롯한 모든 장기들에서 대사 되는데 일부(약 10%)는 호흡을 통하여 또는 소변 및 땀으로 배설된다. 정상적인 상태에서 소량의 알코올을 섭취할 경우 간 장내로 들어온 에탄올은 세포 cytosol 내의 알코올탈수소효소(alcohol dehydrogenase, ADH)와 알데하이드탈수소효소(aldehyde dehydrogenase, ALDH)의 작용에 의해 아세테이트(acetate)로 전환되고, 이는 순환계를 통해 간세포 밖으로 배설되어진다.Absorbed ethanol is metabolized in all organs including the liver, and some (about 10%) is excreted through respiration or urine and sweat. When a small amount of alcohol is ingested under normal conditions, the ethanol that enters the liver is converted to acetate by the action of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cell cytosol. It is excreted out of hepatocytes through the circulatory system.
이중 특히 에탄올의 최초 대사산물인 acetaldehyde는 에탄올에 비해 반응성이 매우 높고 독성이 강하여 알코올성 간 장애의 주원인 물질로 밝혀진 바 있다.In particular, acetaldehyde, the first metabolite of ethanol, has been found to be the main cause of alcoholic liver disorder because it has a very high reactivity and strong toxicity compared to ethanol.
Acetaldehyde는 세포 내 에너지 생성기관인 미토콘드리아(mitochondria)의 호흡을 방해하고 산화적 인산화(oxidative phosphory-lation)반응을 억제하며, 막단백질(cell-membrane protein) 및 콜라겐 단백질과도 결합하여 항체를 생성하기도 하고, 면역학적으로 세포독성을 나타내며 간세포 분비 단백질의 방출기구를 저해하는 것으로 밝혀진 바 있다. 또한, acetaldehyde는 미오피브로블라스트(myofibroblast)의 콜라겐(collagen) 합성을 촉진하여 간 섬유화와 간세포의 변성 종대를 일으키며, 생체내 거대분자와 반응하여 어덕트(adduct)를 형성하기도 한다. 또한, 인체로 섭취된 알코올에 의해서 간 내에 중성지방이 축적되기도 한다. 간에서의 중성지방 축적은 지방산 합성이 증가되기보다는 알코올에 의한 지방산 산화억제가 중성지방축적의 중요인자로 작용하는 것으로 알려져 있다. Acetaldehyde interferes with the respiration of mitochondria, an energy generating organ within cells, inhibits oxidative phosphory-lation, and also binds to cell-membrane proteins and collagen proteins to produce antibodies. , has been found to exhibit immunological cytotoxicity and inhibit the release mechanism of hepatocyte-secreted proteins. In addition, acetaldehyde promotes the synthesis of collagen in myofibroblast to cause liver fibrosis and degenerative enlargement of hepatocytes, and also forms adducts by reacting with macromolecules in vivo. In addition, triglycerides are also accumulated in the liver by alcohol ingested into the human body. It is known that the inhibition of fatty acid oxidation by alcohol acts as an important factor in the accumulation of triglycerides in the liver, rather than increasing fatty acid synthesis.
간에서의 중성지방 축적은 간의 대사장애를 반영해 주며, 계속적인 중성지방축적은 결국 섬유조직의 증식 및 간세포의 손상을 초래하기도 한다. The accumulation of triglycerides in the liver reflects the metabolic disorder of the liver, and the continuous accumulation of triglycerides may eventually lead to the proliferation of fibrous tissue and damage to the hepatocytes.
이와 같은 알코올 대사의 결과, 지방산(脂肪酸)이 많이 만들어져 간에 지방이 축적되는데 이를 알코올성 지방간이라고 한다. 이 알코올성 지방간은 특히 만성 간질환으로 진행하는 경우가 많은데, 알코올성 간염의 10-35%가, 간경변증의 8-20% 정도가 알코올성 지방간과 관련 있는 것으로 보고된 바 있다. 간 내에는 acetaldehyde 뿐만 아니라 각종 약물 및 지방대사산물과 과산화지질의 대사과정, 그리고 C-C결합의 산화적 절단으로 생체에 극히 유해한 것으로 알려진 여러 종류의 aldehyde가 생성된다. Acetaldehyde를 포함한 알데히드의 산화에 관여하는 주효소인 aldehyde dehydrogenase는 간, 콩팥, 심장 및 위를 포함한 많은 장기와 조직에 널리 분포하고, cytosol, mitochondria 및 microsome에도 존재하여 폭넓은 기질 특이성을 보이며, 각종 aldehyde에 대응할 수 있는 약물대사효소의 성격을 지니고 있다.As a result of this alcohol metabolism, a lot of fatty acids (脂肪酸) are made and fat is accumulated in the liver, which is called alcoholic fatty liver. This alcoholic fatty liver often progresses to chronic liver disease. It has been reported that 10-35% of alcoholic hepatitis and 8-20% of cirrhosis are related to alcoholic fatty liver. In the liver, not only acetaldehyde, but also various types of aldehydes known to be extremely harmful to the living body are generated by the metabolic process of various drugs, fat metabolites, lipid peroxide, and oxidative cleavage of C-C bonds. Aldehyde dehydrogenase, the main enzyme involved in the oxidation of aldehydes including acetaldehyde, is widely distributed in many organs and tissues including liver, kidney, heart and stomach, and also exists in the cytosol, mitochondria, and microsomes to show a wide range of substrate specificities, and various aldehydes It has the properties of a drug metabolizing enzyme that can respond to
따라서, 어떤 요인에 의하여 간 내 aldehyde dehydrogenase 활성에 변화가 오게 되면, 이는 활성 알데하이드의 해독 및 물질대사에 중요한 영향을 미치는 것으로 알려져 있다. 이 과정에서 alcohol과 acetaldehyde는 간세포와 뇌세포에 손상을 입히고, 구토 및 두통을 유발시키며, 심하면 오한이나 복통이 유발되며, 이러한 생리적 현상이 숙취의 원인이 되는 것이다.Therefore, when the aldehyde dehydrogenase activity in the liver is changed by any factor, it is known that it has an important effect on the detoxification and metabolism of the active aldehyde. In this process, alcohol and acetaldehyde damage liver cells and brain cells, cause vomiting and headache, and in severe cases cause chills or abdominal pain. These physiological phenomena are the cause of hangovers.
그리고 alcohol dehydrogenase 등이 부족한 사람의 경우에는 간 기능에 더 많은 부담을 주고 정상적인 대사작용이 방해되어 숙취를 일으키는 현상이 더욱 심해지게 된다. 특히, acetaldehyde dehydrogenase는 acetaldehyde가 저 농도이더라도 산화를 개시하는 Ⅱ형과, acetaldehyde가 고농도로 되지 않으면 작용을 하지 않은 Ⅰ형이 있으나, 동양인은 일반적으로 Ⅱ형aetaldehyde dehydrogenase가 결핍 또는 부족하기 때문에 acetaldehyde 산화가 느리고 따라서 산화되지 않은 acetaldehyde 및 ethanol의 유독 작용에 의하여 정상적인 신진대사가 방해받아 여러 숙취 현상을 느끼게 되는 것이다. And in the case of a person lacking alcohol dehydrogenase, etc., it puts more strain on liver function and interferes with normal metabolism, which makes hangovers more severe. In particular, acetaldehyde dehydrogenase has type II, which initiates oxidation even at low concentrations of acetaldehyde, and type I, which does not act unless acetaldehyde is at a high concentration. Due to the slow and therefore non-oxidized toxic action of acetaldehyde and ethanol, normal metabolism is disturbed, and various hangover phenomena are felt.
따라서, 알코올 섭취로 인한 숙취를 제거하고 혈중 알코올 농도를 감소시킬 수 있는 제제를 개발하기 위해 생약 제재 또는 인공제재를 단독 또는 혼합하여 제조된 드링크류가 다수 개발되고 있으며, 민간에서는 북어국이나 콩나물국 등이 숙취해소에 자주 이용되고 있다. Therefore, in order to eliminate a hangover caused by alcohol ingestion and to develop a drug that can reduce blood alcohol concentration, a number of drinks made with herbal or artificial ingredients alone or mixed are being developed. It is often used to relieve hangovers.
그러나, 이러한 생약제제를 이용한 숙취해소용 환이나 음료는 한방 약재에 자체 독성이 존재할 수 있어 오히려 간에 더 무리를 줄 수 있으며, 개발된 제품들은 일부 숙취증상의 해소에만 효과가 있거나 숙취해소 효과가 전반적으로 미미하였으며 심지어는 전신권태, 복부팽만감, 구토 또는 복통 등의 부작용을 유발하는 경우도 있어 아직까지 전반적인 숙취 증상을 효과적으로 제거하거나, 손상된 간을 보호 및 치료함으로써 근본적인 신체 생리기능의 회복을 유도하는 제제의 개발은 미미한 실정이다.However, hangover relieving pills or beverages using these herbal preparations may be toxic to the oriental medicine itself, which may put more strain on the liver. In some cases, it may cause side effects such as general malaise, bloating, vomiting or abdominal pain, so it is still a drug that effectively removes the overall hangover symptom or induces the restoration of the physiological function of the body by protecting and treating the damaged liver. development is insignificant.
숙취해소제에 주로 사용되는 한약재료로는 헛개나무(지구자나무), 무, 사철 쑥, 칡, 감잎, 삼백초, 오가피, 노근, 상심, 금은화, 상엽, 구기자, 천문동, 용안육, 치자, 토사자, 해성차, 녹차, 감초, 갈화, 연화청피, 목향, 귤피, 인삼, 저령, 백복령, 신국, 택사, 건조생강, 백출, 백두구인, 사인, 올리고당, 구루메 등이 있다.Herbal materials mainly used for hangover remedies include sagebrush, radish, wormwood, arrowroot, persimmon leaf, sagebrush, sagebrush, nogeun, heartburn, gold and silver flower, upper leaf, goji berry, cheonmundong, longan meat, gardenia, tosaja, Haeseong tea, green tea, licorice, brown flower, lotus green peel, mokhyang, tangerine peel, ginseng, jeoryeong, baekbokryeong, shinguk, taeksa, dried ginger, baekchul, baekduguin, sine, oligosaccharide, and gourmet.
현재 숙취제거제로서 생약제를 포함하는 각종 드링크제가 시판되고 있고 이러한 드링크제는 음주 후에는 단독 또는 음주 전에는 주류에 첨가하여 음용 되고 있다.Currently, as a hangover remover, various drinks including herbal medicines are on the market, and these drinks are used alone after drinking or added to alcoholic beverages before drinking.
숙취해소용 음료에 첨가되는 성분들은 알코올 흡수를 억제하고, 알코올 대사를 촉진시켜 혈중 알코올 농도를 감소시키며, 알코올로부터 간세포를 보호하고 위장점막을 도포함으로써 알코올에 의한 위장점막손상을 방지하고 위장을 보호하는 기능을 나타내는 것으로 알려져 있다. 또한 장내 소취작용이 강하여 음주 후의 술, 음식 냄새를 제거하고, 장내 유해성분의 생성을 억제하며, 장내 정상세균의 균총을 유지시키며, 음주에 대한 대장 증상을 완화해주는 역할을 나타내기도 한다. 이외에 암모니아 및 인돌 등의 장내 부패산물의 제거, 혈액의 정화, 신장보호작용, 알코올에 의한 숙취현상을 완화시켜 신체 컨디션 저하를 방지하는 효과 등을 나타내는 것으로 알려져 있다.The ingredients added to the hangover relieving drink inhibit alcohol absorption, promote alcohol metabolism, reduce blood alcohol concentration, protect liver cells from alcohol, and apply gastrointestinal mucosa to prevent alcohol-induced gastrointestinal mucosa damage and protect the stomach. It is known to exhibit the function of In addition, since it has a strong intestinal deodorizing effect, it removes the odor of alcohol and food after drinking, suppresses the generation of harmful components in the intestine, maintains the intestinal flora, and relieves colon symptoms related to drinking. In addition, it is known to exhibit effects such as removal of intestinal decay products such as ammonia and indole, blood purification, kidney protection, and alleviating alcohol-induced hangover effects to prevent deterioration of physical condition.
한편, 울금이란 강황(畺黃)의 덩이뿌리를 그대로 또는 주피를 제거하고 쪄서 말린 것으로서, 생강목에 속하는 다년생 식물로서 인도를 중심으로 한 열대, 아열대 지역에서 주로 재배되며 줄기와 뿌리를 식용, 약용 등으로 사용한다.On the other hand, turmeric refers to the tuber root of turmeric as it is or after removing the bark and steaming it, and is a perennial plant belonging to the order Ginger. use, etc.
이러한 울금은 카레가루로 많이 쓰이고 간 해독기능과 항암작용, 상처치료 등의 효과가 있다고 알려져 있다. 한방에서는 어깨 통증, 생리통, 산통(疝痛)의 치료에 처방하는데, 산통(疝痛)이란 갑자기 심하게 일어나는 간헐적 복통으로 복부 내장의 여러 질환에 따르는 증후로 대개 담석증 발작, 신석 발작(腎石發作), 장폐색 등의 경우에 나타난다.Turmeric is widely used as curry powder and is known to have liver detoxification, anticancer effects, and wound healing effects. In oriental medicine, it is prescribed to treat shoulder pain, menstrual pain, and colic. appears in cases such as
또한, 카레 특유의 노란색은 주재료 중의 하나인 울금에서 나오는 천연 색상으로 이 색은 커큐민(curcumin)이라 불리는 물질에 의한 것이다. 커큐민은 동인도산의 생강과에 속하는 식물인 Curcuma longa Linn(Zingiberaceae)의 뿌리에서 추출되어 인도음식에 널리 사용되어 온 폴리페놀성분의 노란색 향신료로 심황의 커큐미노이드이다. 식품첨가물에서는 노란색 색소로 사용되며 향신료로 이용되고 있다.In addition, the characteristic yellow color of curry is a natural color from turmeric, one of the main ingredients, and this color is due to a substance called curcumin. Curcumin is a yellow spice with polyphenols that has been widely used in Indian food extracted from the root of Curcuma longa Linn (Zingiberaceae), a plant belonging to the ginger family from East India. It is a curcuminoid of turmeric. In food additives, it is used as a yellow colorant and as a spice.
이러한 커큐민은 항종양, 항산화, 항아밀로이드와 항염증 작용을 가지고 있는데, 항염증작용은 이코사노이드(eicosanoid) 생합성의 억제에 의해서 기능을 수행한다. 커큐민은 산화에 의한 DNA 손상과 지질과산화를 억제하고 항산화 작용과 청소부 역할을 한다. Curcumin has anti-tumor, antioxidant, anti-amyloid and anti-inflammatory actions, and the anti-inflammatory action is performed by inhibition of eicosanoid biosynthesis. Curcumin inhibits oxidative DNA damage and lipid peroxidation, and acts as an antioxidant and scavenger.
이에 본 발명자들은 숙취해소 효과를 극대화하면서도 기호도를 높일 수 있을 뿐만 아니라 항공기 내 반입도 가능하고 언제 어디서든 간편하게 복용할 수 있는 숙취해소제를 개발하기 위해 계속 연구를 진행하던 중, 상기한 울금의 항산화 및 숙취해소 효과에도 불구하고 실제 제품화에서는 뿌리작물인 울금의 토양미생물 오염도가 높아 충분히 살균되지 못하여 각종 미생물 감염에 의한 변질이나 기호도 열화로 제품화에 어려움을 겪던 중, 특별히 울금분말에 대한 고온 멸균처리 후 사용하면서 기호도가 향상되어 누구든지 거부감 없이 복용할 수 있는 환제를 제조하여 본 발명을 완성하였다.Accordingly, the inventors of the present inventors continued research to develop a hangover reliever that not only maximizes the hangover relieving effect, but also increases the preference, can be carried in the aircraft, and can be conveniently taken anytime, anywhere. And despite hangover relieving effects, in actual commercialization, turmeric, a root crop, has a high soil microbial contamination level, so it was not sterilized sufficiently. The present invention was completed by preparing a pill that anyone can take without any objection due to improved taste while using it.
본 발명에서 해결하고자 하는 기술적 과제는 숙취해소 효과가 극대화되면서도 기호도가 증대시킬 수 있을 뿐만 아니라 언제 어디서든 간편하게 복용할 수 있는 울금을 유효성분으로 포함하는 숙취해소용 환을 제공하기 위한 것이다.The technical problem to be solved in the present invention is to provide a hangover relieving pill containing turmeric as an active ingredient that can be taken conveniently anytime, anywhere as well as increasing the preference while maximizing the hangover relieving effect.
또한, 본 발명에서 해결하고자 하는 기술적 과제는 상기 숙취해소용 환의 제조방법을 제공하기 위한 것이다. In addition, the technical problem to be solved in the present invention is to provide a method for manufacturing the hangover relief ring.
상기한 기술적 과제를 해결하기 위하여, 본 발명에서는 울금 30 내지 40 중량%, 헛개나무 열매 12 내지 16 중량%, 밀크씨쓸 20 내지 30 중량%, 갈근 10 내지 15 중량%, 흑마늘 5 내지 6 중량%, 인진쑥 3 내지 5 중량%, 구기자 3 내지 4 중량%, 및 오미자 1 내지 2 중량%를 포함하는 숙취해소용 조성물인 것을 특징으로 한다.In order to solve the above technical problem, in the present invention, 30 to 40% by weight of turmeric, 12 to 16% by weight of Heotgae tree fruit, 20 to 30% by weight of milk seed, 10 to 15% by weight of ground root, 5 to 6% by weight of black garlic , Injin mugwort 3 to 5% by weight, Goji berry 3 to 4% by weight, and
바람직하게, 상기 숙취해소용 조성물은 기능성 식품 조성물일 수 있으며, 더욱 바람직하게 상기 조성물은 환 제제일 수 있다.Preferably, the hangover relieving composition may be a functional food composition, more preferably the composition may be a pill formulation.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 하기 단계를 포함하는 것을 특징으로 하는 숙취해소용 환 제제의 제조방법을 제공한다:In order to solve the other technical problems described above, the present invention provides a method for producing a pill formulation for relieving hangover, characterized in that it comprises the following steps:
특히, 본 발명에 사용된 울금 분말은 충분히 살균되도록 PET 파우치에 울금가루를 얇게펴 두께 80mm로 한 후 가압고온살균장치에서 압력은 2000psi, 온도 121도로 20분간 살균하는 공정을 거쳐 건조된 울금분말을 사용한다.In particular, the turmeric powder used in the present invention is thinly spread out in a PET pouch to a thickness of 80 mm so that it is sufficiently sterilized, and then the dried turmeric powder is sterilized at a pressure of 2000 psi and a temperature of 121 degrees in a pressure high-temperature sterilizer for 20 minutes. use.
(S1) 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말을 각각 준비하되 상기 울금 분말은 단계;(S1) Prepare turmeric, huskae tree fruit, milk seed extract, black pepper, black garlic, mugwort mugwort, goji berry and omija powder, respectively, but the turmeric powder is a step;
(S2) 상기 단계 (S1)에서 준비된 분말은 울금 30 내지 40 중량%, 헛개나무 열매 12 내지 16 중량%, 밀크씨쓸 20 내지 30 중량%, 갈근 10 내지 15 중량%, 흑마늘 5 내지 6 중량%, 인진쑥 3 내지 5 중량%, 구기자 3 내지 4 중량%, 및 오미자 1 내지 2 중량%를 혼합하는 단계;(S2) The powder prepared in the above step (S1) is 30 to 40 wt% of turmeric, 12 to 16 wt% of Heotgae fruit, 20 to 30 wt% of milk seed, 10 to 15 wt% of ground root, 5 to 6 wt% of black garlic , Injin mugwort 3 to 5% by weight, Goji berry 3 to 4% by weight, and the step of mixing 1 to 2% by weight of Schisandra;
(S3) 상기 단계 (S2)에서 혼합된 혼합물에 물을 가하여 반죽한 다음 롤밀로 압연하는 단계;(S3) kneading by adding water to the mixture mixed in step (S2), and then rolling with a roll mill;
(S4) 상기 단계 (S3)에서 압연된 혼합물을 환 형태로 제환하는 단계; 및(S4) ring-closing the mixture rolled in step (S3) in the form of a ring; and
(S5) 상기 단계 (S4)에서 제환된 환을 60 내지 70℃에서 7 내지 9 시간 동안 건조하는 단계.(S5) drying the ring recirculated in step (S4) at 60 to 70° C. for 7 to 9 hours.
본 발명은 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말의 혼합물을 유효성분으로 포함하는 숙취제거용 환 제제로 복용하기 간편할 뿐만 아니라 월등한 숙취제거 효과가 있으면서 색감 및 향이 개선되어 기호도가 증대될 수 있는 바, 항공기내든 언제 어디서든 휴대하며 거부감 없이 유용하게 이용될 수 있는 효과가 있다.The present invention is a hangover-removing pill containing as an active ingredient a mixture of turmeric, sagebrush fruit, milk seed extract, black root, black garlic, wormwood, goji berry and omija powder as an active ingredient. As the color and fragrance are improved, the preference can be increased, and it has the effect that it can be carried and used usefully without any objection, anytime, anywhere in the aircraft.
특히, 환 제제의 경우 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말을 사용함으로써 결착제 역할이 되어 제형화가 매우 유리한 이점도 있으며, 고온 가압 멸균된 울금 분말을 주성분으로 사용함으로 인해 색감, 향 및 전체적인 기호도가 대폭 향상될 수 있다.In particular, in the case of pill formulation, it has a very advantageous formulation by using powders of turmeric, sagebrush, milk seed extract, black pepper, black garlic, ginseng mugwort, goji berry, and omija powder, which is very advantageous in formulation. Due to its use, color, fragrance, and overall preference can be significantly improved.
본 명세서에 첨부되는 다음의 도면들은 본 발명의 바람직한 실시예를 예시하는 것이며, 전술한 발명의 내용과 함께 본 발명의 기술사상을 더욱 이해시키는 역할을 하는 것이므로, 본 발명은 그러한 도면에 기재된 사항에만 한정되어 해석되어서는 아니 된다.
도 1은 본 발명의 숙취해소용 환 제제의 유효성분의 사진이다.
도 2는 본 발영 숙취해소용 환 제제의 세균에 대한 안전성을 측정한 결과이다.
도 3은 본 발명의 숙취해소용 환의 알코올 유발 간세포 손상 보호 효과 측정한 결과를 나타낸 것이다.
도 4는 본 발명의 숙취해소용 환의 투여 후 간 중량의 변화를 나타낸 결과를 나타낸 것이다.
도 5는 본 발영 숙취해소용 환 제제에 사용된 울금가루의 멸균을 위해 개량된 공정을 갖는 가압 살균기 사진이다.The following drawings attached to this specification illustrate preferred embodiments of the present invention, and serve to further understand the technical idea of the present invention together with the above-described content of the invention, so the present invention is limited to the matters described in those drawings It should not be construed as being limited.
1 is a photograph of the active ingredient of the pill formulation for relieving a hangover of the present invention.
Figure 2 is a result of measuring the safety against bacteria of the present hangover relieving pill formulation.
Figure 3 shows the results of measuring the alcohol-induced hepatocellular damage protective effect of the hangover relieving pill of the present invention.
Figure 4 shows the results showing the change in liver weight after administration of the hangover relieving pill of the present invention.
Figure 5 is a photo of a pressure sterilizer having an improved process for sterilization of turmeric powder used in the present pill formulation for hangover relief.
이하에서는 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서는 울금 30 내지 40 중량%, 헛개나무 열매 12 내지 16 중량%, 밀크씨쓸 20 내지 30 중량%, 갈근 10 내지 15 중량%, 흑마늘 5 내지 6 중량%, 인진쑥 3 내지 5 중량%, 구기자 3 내지 4 중량%, 및 오미자 1 내지 2 중량%를 포함하는 것을 특징으로 하는 숙취해소용 조성물을 제공한다.In the present invention, 30 to 40% by weight of turmeric, 12 to 16% by weight of Heotgae fruit, 20 to 30% by weight of milk seed, 10 to 15% by weight of ground root, 5 to 6% by weight of black garlic, 3 to 5% by weight of wormwood, Goji berry It provides a composition for relieving a hangover, characterized in that it contains 3 to 4% by weight, and 1 to 2% by weight of omija.
본 발명에 따른 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말의 혼합물을 포함하는 조성물은 숙취해소에 있어서 극대화된 시너지 효과를 나타낸다. A composition comprising a mixture of turmeric, sagebrush fruit, milk seed extract, black pepper, black garlic, wormwood, goji berry and omija powder according to the present invention exhibits a maximized synergistic effect in relieving hangover.
본 발명의 숙취해소용 조성물의 유효성분인 울금은 카레가루로 많이 쓰이고 간 해독기능과 항암작용, 상처치료 등의 효과가 있다고 알려져 있다. 한방에서는 어깨 통증, 생리통, 산통(疝痛)의 치료에 처방하는데, 산통(疝痛)이란 갑자기 심하게 일어나는 간헐적 복통으로 복부 내장의 여러 질환에 따르는 증후로 대개 담석증 발작, 신석 발작(腎石發作), 장폐색 등의 경우에 나타난다. 카레 특유의 노란색은 주재료 중의 하나인 울금에서 나오는 천연 색상으로 이 색은 커큐민(curcumin)이라 불리는 물질에 의한 것이다. 커큐민은 항종양, 항산화, 항아밀로이드와 항염증 작용을 가지고 있는데, 항염증작용은 이코사노이드(eicosanoid) 생합성의 억제에 의해서 기능을 수행한다. 커큐민은 산화에 의한 DNA 손상과 지질과산화를 억제하고 항산화 작용과 청소부 역할을 한다. Turmeric, the active ingredient of the composition for relieving hangovers of the present invention, is widely used as curry powder and is known to have effects such as liver detoxification, anticancer action, and wound healing. In oriental medicine, it is prescribed to treat shoulder pain, menstrual pain, and colic. appears in cases such as The unique yellow color of curry is a natural color from turmeric, one of the main ingredients, and this color is due to a substance called curcumin. Curcumin has anti-tumor, antioxidant, anti-amyloid and anti-inflammatory actions, and the anti-inflammatory action is performed by inhibition of eicosanoid biosynthesis. Curcumin inhibits oxidative DNA damage and lipid peroxidation, and acts as an antioxidant and scavenger.
본 발명의 숙취해소용 조성물에서는 울금 분말을 주성분으로 사용함으로 인해 색감, 향 및 전체적인 기호도를 대폭 향상시킬 수 있으나, 울금이 뿌리작물이기 때문에 토양으로부터 많은 미생물이 오염되어 있어 제품화 과정에서 변질이나 기호성의 열화 현상이 심해 이에 따라 울금가루를 특별한 조건하에서 살균하여 사용함으로써 문제를 해결하였다.In the composition for relieving a hangover of the present invention, color, fragrance and overall preference can be greatly improved by using turmeric powder as a main component, but since turmeric is a root crop, many microorganisms are contaminated from the soil, so it may cause deterioration or palatability in the manufacturing process. The problem was solved by sterilizing and using turmeric powder under special conditions.
본 발명 울금을 유효성분으로 포함하는 숙취해소용 환을 제조함에 있어서 울금분말의 변질과 이취 발생을 막기위하여 울금 가압살균 장치(도 5 참조)를 개량하여 최적화 시험을 거쳐 제조공정을 세팅하였는바, PET 파우치에 울금가루를 얇게펴 두께 80mm로 한 후 가압고온살균장치에서 압력은 2000psi, 온도 121도로 20분간 살균하는 공정을 거쳐 건조된 울금분말을 제조하여 사용 했다.In order to prevent the deterioration of the turmeric powder and the occurrence of off-flavor in manufacturing the hangover relieving pill containing turmeric as an active ingredient of the present invention, the turmeric pressure sterilization device (see FIG. 5) was improved and the manufacturing process was set through an optimization test, After thinly spreading turmeric powder on a PET pouch to make it 80mm thick, it was sterilized at a pressure of 2000psi and a temperature of 121°C for 20 minutes in a pressurized high-temperature sterilizer to prepare and use dried turmeric powder.
본 발명의 숙취해소용 조성물의 유효성분인 헛개나무는 갈매나무과의 낙엽활엽교목으로, 열매는 주정중독, 소변 불리, 구토에 효능이 있고, 과경은 건위, 자양보혈에 효과가 있다. 과병과 줄기는 단맛과 향을 내어 식용, 과주(果酒) 및 약용으로 주독(酒毒)을 제거하는데 사용되어왔으며 특히 과병은 사포닌을 다량 함유하고 있다. 헛개나무는 술을 썩히는 작용이 있고, 생즙은 술독을 풀고 구역질을 멈추게 하므로 숙취 제거와 알코올 분해에 탁월한 효과가 있다. 또한 과음 시 부작용으로 나타나는 황달, 지방간, 간경화증, 위장병 및 대장염 등의 간 기능 보호에 효능이 뛰어나다.The active ingredient of the composition for relieving hangovers of the present invention, Heotgae tree, is a deciduous broad-leaved tree of the Buckwheat family, and the fruit is effective in alcohol poisoning, urinary discomfort, and vomiting, and the fruit tree is effective in health and nourishment. Gwabyeong and stems are sweet and fragrant, and have been used for food, fruit wine, and medicinal purposes to remove poison. Heotgae tree has the effect of rotting alcohol, and raw juice is excellent for removing hangovers and decomposing alcohol because it relieves alcohol poisoning and stops nausea. In addition, it is effective in protecting the liver function such as jaundice, fatty liver, cirrhosis, gastrointestinal disease and colitis, which are side effects of excessive drinking.
본 발명의 숙취해소용 조성물의 유효성분인 밀크씨슬(Silybum marianum)은 국화과 식물의 일종으로, 씨앗에서 추출한 실리마린 성분이 간 건강에 도움을 주는 것으로 알려져 있다. 밀크씨슬은 알코올 또는 기타 독성 물질로 인한 간세포를 복구시키는 효능, 및 새로운 간세포가 독소로 인해 파괴되는 것을 방지하고 염증을 줄여주는 등 강력한 항산화 효능을 지닌 것으로 알려져 있다. Milk thistle (Silybum marianum), an active ingredient of the composition for relieving hangovers of the present invention, is a kind of plant in the Asteraceae family, and it is known that silymarin extracted from seeds helps liver health. Milk thistle is known to have strong antioxidant effects, such as the effect of repairing liver cells caused by alcohol or other toxic substances, and preventing the destruction of new hepatocytes by toxins and reducing inflammation.
본 발명의 숙취해소용 조성물의 유효성분인 갈근은 콩과 (Leguminosae)에 속하는 다년생 만경식물인 칡 (Pueraria thunbergiana BENTH)의 괴경을 칭하는 것으로 푸에라린(puerarin), 푸에라린 자일로스 (puerarin xylose), 디이드진(daidzein), 시토스테롤 (sitosterol) 등의 물질을 함유하고 있으며, 혈류증가작용, 진경작용, 해열작용 등을 갖는 것으로 알려져 있다.The active ingredient of the composition for relieving hangovers of the present invention, galgeun, refers to the tuber of kudzu (Pueraria thunbergiana BENTH), a perennial mangyeong plant belonging to the leguminosae family. Puerarin, puerarin xylose ), daidzein, sitosterol, etc. are contained, and are known to have blood flow increasing action, antispasmodic action, antipyretic action, and the like.
본 발명의 숙취해소용 조성물의 유효성분인 흑마늘은 마늘을 숙성시켜 얻어지는 것으로, 마늘에 함유된 알리신이 분해되어 마늘 고유의 강한 향이 발생하지 않으며, 유효성분인 알린의 함량을 유지하며, 알리나아제에 의한 알리신으로의 전환을 막아 추가적인 냄새의 발생을 억제할 수 있고 매운맛을 제거할 수 있는 효과가 있다.Black garlic, which is the active ingredient of the composition for relieving hangovers of the present invention, is obtained by aging garlic. Allicin contained in garlic is decomposed and does not generate a strong flavor inherent in garlic. By preventing the conversion to allicin by
본 발명의 숙취해소용 조성물의 유효성분인 인진쑥(Artemisia capillaris)은 우리나라에서 자생하는 식물로 국화과(compositae)의 다년생 초본 식물이며, 더위지기, 애탕쑥이라고도 불린다. 인진쑥은 주로 어린순이 사용되며, 항염, 항균, 항여드름, 항산화, 이뇨제, 황달 등에 효과가 있는 것으로 알려져 있다. 주요 성분으로는 폴리페놀의 일종인 클로로겐산(chlorogenic acid), 카페익산(caffeic acid)부터 정유 성분인 올레산(oleic acid), 리놀레산(linoleic acid)까지 다양한 성분들이 포함되어 있다.Artemisia capillaris, an active ingredient of the composition for relieving hangovers of the present invention, is a herbaceous perennial plant of the Compositae family, which is a plant that grows wild in Korea, and is also referred to as scorched wormwood. Injin mugwort mainly uses young shoots and is known to be effective in anti-inflammatory, antibacterial, anti-acne, antioxidant, diuretic, and jaundice. The main components include various components from chlorogenic acid and caffeic acid, which are types of polyphenols, to oleic acid and linoleic acid, which are essential oil components.
본 발명의 숙취해소용 조성물의 유효성분인 구기자는 가짓과에 속하는 구기자나무의 열매로서, 베타인 성분이 함유되어 지방간 예방 및 치료에 효능이 있고 비타민C, 루틴이 함유되어 혈관을 튼튼하게 하고 저혈압 치료에 효능도 있다.Goji berry, the active ingredient of the composition for relieving hangover of the present invention, is a fruit of Goji berry belonging to the family Gajitaceae. It contains betaine, which is effective for the prevention and treatment of fatty liver, and contains vitamin C and rutin to strengthen blood vessels and lower blood pressure. It is also effective in treatment.
본 발명의 숙취해소용 조성물의 유효성분인 오미자는 오미자과의 덩굴성 낙엽수 나무에서 열리는 과일로서, 달고 쓰고 시고 맵고 짠 다섯 가지의 맛이 난다고 하여 오미자라고 불린다. 오미자는 일반적으로 혈류 개선, 고혈압, 뇌줄중, 심혈관 질환 예방, 면역력 개선, 당뇨병 예방, 간기능 개선, 원기 회복, 호흡기 질환 개선 효능이 있는 것으로 알려져 있다. Omija, the active ingredient of the composition for relieving hangovers of the present invention, is a fruit that grows on a deciduous deciduous tree of the Omija family. Omija is generally known to have the effects of improving blood flow, preventing hypertension, stroke, cardiovascular disease, improving immunity, preventing diabetes, improving liver function, restoring energy, and improving respiratory diseases.
본 발명의 하나의 구현예에 따르면, 상기 숙취해소용 조성물은 기능성 식품 조성물일 수 있다.According to one embodiment of the present invention, the hangover relieving composition may be a functional food composition.
본 발명에 따른 숙취해소용 식품 조성물은 유효성분을 식품학적으로 허용된 담체에 혼입시킨 형태로 제조될 수 있다. The food composition for relieving a hangover according to the present invention may be prepared in a form in which the active ingredient is incorporated into a foodologically acceptable carrier.
상기 제제화 경우에는 통상 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 그러한 고형 제제는 유효성분에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘 카르보네이트, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 일반적으로 사용되는 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. In the case of the formulation, it may be prepared using a diluent or excipient such as a commonly used filler, extender, binder, wetting agent, disintegrant, and surfactant. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the active ingredient, for example, starch, calcium carbonate, sucrose, lactose, gelatin. It can be prepared by mixing, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. can
본 발명의 하나의 구현예에 따르면, 본 발명의 숙취해소용 제제는 환 제제의 형태로 제형화될 수 있다. According to one embodiment of the present invention, the hangover relieving agent of the present invention may be formulated in the form of a pill formulation.
본 발명에 따른 숙취해소용 제제의 투여량은 개체의 연령, 체중, 성별, 신체 상태 등을 고려하여 선택된다. The dosage of the hangover relieving agent according to the present invention is selected in consideration of the individual's age, weight, sex, physical condition, and the like.
본 발명의 하나의 구현예에 따르면, 본 발명의 숙취해소용 환 제제는 음주 전 또는 음주 후에 간편하게 복용할 수 있다.According to one embodiment of the present invention, the pill formulation for relieving a hangover of the present invention can be conveniently taken before or after drinking.
본 발명에서는 하기 단계를 포함하는 것을 특징으로 하는 숙취해소용 환 제제의 제조방법을 제공한다:The present invention provides a method for preparing a pill formulation for relieving hangover, comprising the following steps:
(S1) 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말을 준비하는 단계;(S1) preparing the powder of turmeric, Heotgae tree fruit, milk seed extract, garlic root, black garlic, wormwood, Goji berries and Schisandra;
(S2) 상기 단계 (S1)에서 준비된 울금 30 내지 40 중량%, 헛개나무 열매 12 내지 16 중량%, 밀크씨쓸 20 내지 30 중량%, 갈근 10 내지 15 중량%, 흑마늘 5 내지 6 중량%, 인진쑥 3 내지 5 중량%, 구기자 3 내지 4 중량%, 및 오미자 1 내지 2 중량%를 혼합하는 단계;(S2) 30 to 40% by weight of turmeric prepared in the step (S1), 12 to 16% by weight of hemp seeds, 20 to 30% by weight of milk seed extract, 10 to 15% by weight of ground root, 5 to 6% by weight of black garlic, Injin mugwort 3 to 5% by weight, 3 to 4% by weight of Goji berry, and 1 to 2% by weight of Schisandra;
(S3) 상기 단계 (S2)에서 혼합된 혼합물에 물을 가하여 반죽한 다음 롤밀로 압연하는 단계;(S3) kneading by adding water to the mixture mixed in step (S2), and then rolling with a roll mill;
(S4) 상기 단계 (S3)에서 압연된 혼합물을 환 형태로 제환하는 단계; 및(S4) ring-closing the mixture rolled in step (S3) in the form of a ring; and
(S5) 상기 단계 (S4)에서 제환된 환을 60 내지 70℃에서 7 내지 9 시간 동안 건조하는 단계.(S5) drying the ring recirculated in step (S4) at 60 to 70° C. for 7 to 9 hours.
본 발명의 하나의 구현예에 따르면, 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자를 각각 분말 형태로 사용함으로써 결착제 역할이 되어 제형화가 매우 유리한 이점이 있다.According to one embodiment of the present invention, by using each of turmeric, honeysuckle fruit, milk seed extract, black root, black garlic, wormwood, goji berry, and omija in powder form, it serves as a binder, and formulation has a very advantageous advantage.
본 발명의 하나의 구현예에 따르면, 상기 숙취해소용 조성물은 기능성 식품 조성물일 수 있다.According to one embodiment of the present invention, the hangover relieving composition may be a functional food composition.
이와 같이, 본 발명에 따른 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말의 혼합물을 포함하는 조성물은 숙취해소에 있어서 극대화된 시너지 효과를 나타낸다. 특히 환 제제의 경우 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말을 사용함으로써 결착제 역할이 되어 제형화가 매우 유리한 이점도 있으며, 울금 분말을 주성분으로 사용함으로 인해 색감, 향 및 전체적인 기호도가 대폭 향상될 수 있다. As described above, the composition comprising a mixture of turmeric, honeysuckle tree fruit, milk seed extract, black garlic, ginseng wormwood, goji berry and omija powder according to the present invention exhibits a maximized synergistic effect in relieving a hangover. In particular, in the case of pills, it has a very advantageous formulation by acting as a binder by using powders of turmeric, sagebrush, milk seed extract, black root, black garlic, wormwood, goji berries and omija. Fragrance and overall palatability can be significantly improved.
따라서, 본 발명의 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말의 혼합물을 유효성분으로 포함하는 숙취제거용 환 제제로 복용하기 간편할 뿐만 아니라 월등한 숙취제거 효과가 있으면서 색감 및 향이 개선되어 기호도가 증대될 수 있는 바, 황공기 내든 언제 어디서든 휴대하며 거부감 없이 유용하게 이용될 수 있을 것으로 기대된다.Therefore, as an active ingredient, it is a pill preparation for hangover that contains a mixture of turmeric, sagebrush fruit, milk seed extract, black pepper, black garlic, wormwood, Goji berry and omija powder of the present invention as an active ingredient. It is expected that it will be able to be used effectively without any repulsion by carrying it anywhere, anytime, even in the dusty air, as the color and fragrance are improved and the preference can be increased.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다. Hereinafter, examples and the like will be described in detail to help the understanding of the present invention. However, the embodiments according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.
<실시예 1> 숙취해소용 환 제제의 제조<Example 1> Preparation of pills for hangover relief
도 1에 나타낸 바와 같은 본 발명의 숙취해소용 환 제제의 유효성분 재료를 각각 입수하였다. 도 1은 본 발명의 숙취해소용 환 제제의 유효성분의 사진이다.As shown in Figure 1, each of the active ingredients of the pill formulation for relieving a hangover of the present invention was obtained. 1 is a photograph of the active ingredient of the pill formulation for relieving a hangover of the present invention.
본 발명 울금을 유효성분으로 포함하는 숙취해소용 환을 제조함에 있어서 울금분말의 변질과 이취 발생을 막기위하여 울금 가압살균 장치를 개량하여 최적화 시험을 거쳐 제조공정을 세팅하였는바, PET 12mm 파우치에 울금가루를 얇게펴 두께 80mm로 한 후 가압고온살균장치에서 압력은 2000psi, 온도 121도로 20분간 살균하는 공정을 거쳐 건조된 울금분말을 제조하여 사용 했다.In order to prevent the deterioration of the turmeric powder and the occurrence of off-flavor in manufacturing the pill for relieving hangover containing turmeric as an active ingredient of the present invention, the turmeric pressure sterilization device was improved and the production process was set through an optimization test, turmeric in a PET 12mm pouch After spreading the powder thinly to a thickness of 80 mm, and then sterilizing the powder at a pressure of 2000 psi and a temperature of 121 ° C for 20 minutes in a pressurized high-temperature sterilizer, dried turmeric powder was prepared and used.
울금을 유효성분으로 포함하는 숙취해소용 조성물 및 이의 제조방법Composition for relieving hangover containing turmeric as an active ingredient and method for preparing the same
하기 표 1에 나타낸 조성과 같이, 울금 분말 35 중량%, 헛개나무 열매 분말 14 중량%, 밀크씨슬 분말 25 중량%, 갈근 분말 12 중량%, 흑마늘 분말 5.6 중량%, 인진쑥 분말 4 중량%, 구기자 분말 3.2 중량%, 및 오미자 1.2 중량%를 혼합한 다음 반죽하여 롤밀로 압연한 다음 제환하고 65℃에서 8시간 동안 건조하여 숙취해소용 환 제제를 제조하였다.As shown in Table 1 below, 35% by weight of turmeric powder, 14% by weight of mulberry fruit powder, 25% by weight of milk thistle powder, 12% by weight of ground root powder, 5.6% by weight of black garlic powder, 4% by weight of wormwood powder, wolfberry After mixing 3.2 wt% of powder, and 1.2 wt% of Schisandra Schisandra, kneaded and rolled with a roll mill, then made into pills and dried at 65° C. for 8 hours to prepare a pill formulation for relieving hangovers.
울금을 유효성분으로 포함하는 숙취해소용 조성물 및 이의 제조방법Composition for relieving hangover containing turmeric as an active ingredient and method for preparing the same
<시험예 1> 숙취해소용 환 제제의 이화학적 실험<Test Example 1> Physicochemical experiment of pills for hangover relief
(1) 색도(Lab값)(1) Chromaticity (Lab value)
시료의 색도는 분광측색계(SPECTROPHOTOMETER CM-5)를 이용하여 3반복 측정 후 L*, a*, b* 평균값으로 산출하였다.The chromaticity of the sample was calculated as the average value of L * , a * , b * after three repeated measurements using a spectrophotometer (SPECTROPHOTOMETER CM-5).
L* : 반사율(인간의 시감과 같은 명도)을 나타내며, 0∼100까지의 단계로 소수점 이하 단위로도 표현할 수 있다.L * : Represents reflectance (brightness similar to human vision), and can be expressed in units of less than a decimal point in steps from 0 to 100.
a* : 색도 다이어그램으로 +a*는 빨강, -a*는 초록 방향을 나타낸다.a * : In the chromaticity diagram, +a * indicates the direction of red and -a * indicates the direction of green.
b* : 색도 다이어그램으로 +b*는 노랑, -b*는 파랑 방향을 나타낸다.b * : In the chromaticity diagram, +b * indicates yellow and -b * indicates blue direction.
(2) 수분함량(2) moisture content
시료 3g을 건조감량법으로 측정하여 하기 수학식 1에 따라 산술하였다. 3 g of the sample was measured by the loss-on-drying method, and arithmetic was performed according to
① 식품공전 제9 일반시험법 1.1.1.1 건조감량법 참고① Refer to Food Codex No. 9 General Test Method 1.1.1.1 Loss on drying method
② 미리 가열하여 항량으로 만든 칭량접시에 검체 3~5 g 정밀 계량② Precisely weigh 3~5 g of sample on a weighing dish made with constant weight by heating
③ 각 식품마다 규정된 온도의 건조기에 넣어 3~5 시간 건조③ For each food, put it in a dryer at the prescribed temperature and dry it for 3 to 5 hours
④ 데시케이터 중에서 약 30분간 식히고 무게 측정④ Cool for about 30 minutes in a desiccator and weigh
⑤ 칭량접시 1~2시간 건조하여 항량이 될 때까지 같은 조작 반복⑤ Dry the weighing dish for 1-2 hours and repeat the same operation until it becomes constant weight
(3) 수분활성도(3) Water activity
수분활성도 측정기(AQS-31, human corporation)를 이용하여 시료를 플라스틱용기에 절반정도 담아 3반복 측정 후 평균값을 산출하였다.Using a water activity measuring instrument (AQS-31, human corporation), half of the sample was placed in a plastic container and the average value was calculated after three repeated measurements.
(4) 물성 측정 (4) Measurement of physical properties
식품물성분석기(Texture Analyser, TAXTplus, Stable Micro System)을 이용하여 Hardness(g)을 3반복 측정 후 평균값을 산출하였다.Hardness (g) was measured three times using a food property analyzer (Texture Analyzer, TAXTplus, Stable Micro System), and then the average value was calculated.
a(붉은색) : 11.56
b(황색) : 28.66L (brightness) : 40.08
a (red): 11.56
b (yellow): 28.66
상기 표 2에서 보듯이, 색도의 경우 b값(황색)이 28.66으로 측정되었다. 이는 숙취해소 환에 함유된 울금 분말의 특성으로 인한 것으로 판단되고, 수분함량은 2.98%, 수분활성도는 0.468로 건조 된 환제품의 특성에 맞게 낮게 측정되었다. 또한, 물성측정 결과 환의 Hardness는 11543g 으로 측정되었다.As shown in Table 2 above, in the case of chromaticity, the b value (yellow) was measured to be 28.66. This is judged to be due to the characteristics of the turmeric powder contained in the hangover relieving pills, and the moisture content was 2.98% and the water activity was 0.468, which was low to match the characteristics of the dried pills. In addition, as a result of physical property measurement, the hardness of the ring was measured to be 11543 g.
<시험예 2> 숙취해소용 환 제제의 세균 안전성 측정<Test Example 2> Bacterial safety measurement of hangover relieving pills
(1) 대장균, 대장균군(1) E. coli, coliform group
시험용액 1 mL와 각 10배 단계 희석액 1 mL를 대장균 및 대장균군 건조필름배지에 접종한 후 35∼37℃에서 24~48시간 배양하여 대장균 및 대장균군 유무를 확인 하였다.1 mL of the test solution and 1 mL of each 10-fold dilution solution were inoculated on dry film medium for E. coli and coliform groups, and then cultured at 35-37°C for 24-48 hours to confirm the presence of E. coli and coliform groups.
(2) 일반세균(2) General bacteria
시험용액 1 mL와 각 10배 단계 희석액 1 mL를 세균수 건조필름배지에 접종한 후 35∼37℃에서 24∼48시간 배양하여 생성된 붉은 집락수를 계산하고 그 평균 집락 수에 희석배수를 곱하여 계산하였다.After inoculating 1 mL of the test solution and 1 mL of each 10-fold dilution on a dry film medium for bacterial count, incubate at 35-37°C for 24-48 hours to calculate the resulting number of red colonies and multiply the average number of colonies by the dilution factor. Calculated.
(3) 효모, 곰팡이(3) yeast, mold
시험용액 1 mL와 각 10배 단계 희석액 1 mL를 효모ㆍ곰팡이 건조필름배지에 접종한 후 25~27℃에서 36∼60시간 배양한다. 효모는 작고 녹푸른 균체, 곰팡이는 넓고 핵과 가장자리의 선이 불분명한 균체를 확인 후 계산하고 그 평균 집락 수에 희석배수를 곱하여 계산하였다.
각 세균에 대한 농산가공품 기준규격은 다음과 같다.The standard specifications for processed agricultural products for each bacteria are as follows.
- 대장균군 : n=5, c=1, m=0, M=10 (살균제품에 한한다)- Coliform group: n=5, c=1, m=0, M=10 (limited to sterilized products)
- 세균수 : n=5, c=0, m=0 (멸균제품에 한한다)- Number of bacteria: n=5, c=0, m=0 (limited to sterilized products)
상기에서, above,
n은 한 로트에서 임의의 샘플을 수집한 뒤의 실험 반복 수이고,n is the number of iterations of the experiment after collecting a random sample from one lot,
c는 한 검정단위 중에 미생물 균수 기준을 초과한 검체수의 최대 허용 수이고,c is the maximum allowable number of samples exceeding the microbial count standard in one assay unit,
m은 g당 최대한계 생균수 또는 특정 균수 (minimum)이고,m is the maximum number of viable cells per g or a specific number of bacteria (minimum),
M은 불합격과 조건합격을 결정하는 기준이 되는 균수 (Maximum)이다.M is the number of bacteria (Maximum) that is the criterion for determining rejection and condition pass.
도 2는 숙취해소용 환 제제의 세균에 대한 안전성을 측정한 결과이다. 도 2에서 보듯이, 숙취해소환 제품의 미생물 실험 결과, 대장균ㆍ대장균군, 효모ㆍ곰팡이는 불검출되었으며, 일반세균의 경우 매우 소량 검출되어 미생물 안전성 확보된 것으로 판단할 수 있다.Figure 2 is a result of measuring the safety of the pill formulation for hangover relief against bacteria. As shown in FIG. 2, as a result of the microbial test of the hangover relieving product, E. coli, coliform group, yeast, and mold were not detected, and in the case of general bacteria, it can be determined that microbial safety has been secured by detecting a very small amount.
<시험예 3> 숙취해소용 환 제제의 간세포 손상 보호효과 측정<Test Example 3> Measurement of the hepatocellular damage protective effect of a pill formulation for relieving hangover
평균 체중 170-180g의 Sprague-Dawley rat (male) (입수처: (주) 샘타코 BIO KOREA)에게 고형시료와 수돗물을 자유 섭취케 하여 1주간 예비 사육 후 사용하였다. 동물사육실 조건은 온도: 22±2℃, 습도:50±5%, 명암: 12시간 light/dark cycle 주기로 관리하였다.Sprague-Dawley rats (male) with an average weight of 170-180 g (obtained from: Samtaco BIO KOREA) were allowed to freely ingest solid samples and tap water, and were used after preliminary breeding for 1 week. The conditions of the animal room were temperature: 22±2°C, humidity: 50±5%, and contrast: 12 hours light/dark cycle.
순화기간 중 이상이 발생한 개체와 정상적으로 체중이 증가하지 않은 개체를 제외한 후, 하기 표 3에 따라 각 군간 평균체중 및 표준편차가 균일하도록 군 분리를 실시하였다. 군 분리 후 잔여동물은 투여 개시일까지 유지하고 그 이후에는 안락사하였다. 대조군은 여명808 투여농도 (6.2 ml/kg)는 시중 여명808 1회 섭취량 (140 ml)을 기준으로 환산하여 사용하였으며, 의뢰 시험물질은 성인 1회 섭취량 3g을 가정한 기준으로 환산한 값을 중농도 (300 mg)으로 설정하였다.After excluding individuals with abnormalities during the acclimatization period and individuals who did not gain weight normally, group separation was performed according to Table 3 below so that the average weight and standard deviation between each group were uniform. After group separation, the remaining animals were maintained until the start date of administration, after which they were euthanized. For the control group, the dose concentration (6.2 ml/kg) of Dyeongyeong 808 was converted based on the market dose of Dyeongyeong 808 per serving (140 ml), and the requested test substance was converted based on the assumption that an adult dose of 3g was used. degrees (300 mg).
1주일간의 순화기간 후, 시험물질을 1일 1회 총 3일 동안 반복 투여하였다. 복합 분말(실시예 1의 숙취해소용 환) 1, 2 및 3 시험군은 경구 투여를 실시하였다. 각 시험군에 투여로 인해 유발되는 스트레스 및 복용량을 동일하게하기 위하여, control군, 음성대조군 및 양성대조군, 복합 분말 1, 2 및 3 투여군들과 같은 양의 생리식염수를 경구 투여하였다. 경구 투여 1시간 후, 알코올을 구강 투여하였다.After a one-week acclimatization period, the test substance was repeatedly administered once a day for a total of 3 days. Complex powder (hangover pill of Example 1) 1, 2 and 3 test groups were administered orally. In order to equalize the dose and stress induced by administration to each test group, the same amount of physiological saline as the control group, negative control group and positive control group, and
(1) 알코올 유발 간세포 손상 보호 효과(in vitro) 측정(1) Measurement of alcohol-induced hepatocellular injury protective effect (in vitro)
96-well plate에 세포수가 104-106 cell/㎖가 되도록 seeding 하고 24시간 지난 후, 시료를 다양한 농도로 처리하였으며 시료 처리 24시간 후, MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyl- tetrazolium bromide; Sigma, USA) assay로 세포 생존율을 측정하였다. 배지의 10분의 1에 해당하는 MTT 용액(5 mg/mL)을 가하고 37 ℃, 5% CO2 incubator에서 4 h 추가 배양하여 MTT를 환원시켜 formazan을 형성하도록 하였다. 그런 다음 formazan이 유실되지 않도록 배지를 제거한 후 암조건에서 30min 간 건조 후에 DMSO을 첨가하여 10 min 교반 후 ELISA reader를 이용하여 540 nm에서 흡광 값을 측정하였다.After seeding the 96-well plate so that the number of cells became 104-106 cell/ml, 24 hours later, samples were treated at various concentrations. 24 hours after sample treatment, MTT (3-[4,5-dimethylthiazole-2-yl] Cell viability was measured by -2,5-diphenyl- tetrazolium bromide (Sigma, USA) assay. MTT solution (5 mg/mL) corresponding to one-tenth of the medium was added, and further cultured for 4 h at 37 °C, 5% CO2 incubator to reduce MTT to form formazan. Then, the medium was removed so that the formazan was not lost, and after drying for 30 min in the dark, DMSO was added, stirred for 10 min, and the absorbance value was measured at 540 nm using an ELISA reader.
① 시료의 농도 결정을 위한 시료 독성 확인① Check the toxicity of the sample to determine the concentration of the sample
알코올 유발 간손상 보호효과를 측정하기 위한 복합 분말의 처리농도 결정을 위한 실험목적으로 복합 분말 자체의 안전 농도 범위 결정시험을 실시하였다. For the purpose of the experiment to determine the treatment concentration of the composite powder to measure the alcohol-induced liver damage protective effect, a test for determining the safe concentration range of the composite powder itself was conducted.
복합 분말은 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100 μl/ml의 농도로 흰쥐에서 적출한 간세포를 일차 배양한 세포에 처리한 후 24시간 후 MTT로 확인한 결과, 1 μl/ml의 복합 분말에서 세포 독성이 관찰되었고 30, 100 μl/ml 농도에서는 높은 독성을 보였다.The complex powder was treated with primary cultured cells of hepatocytes extracted from rats at concentrations of 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100 μl/ml, and 24 hours later, as a result of checking by MTT, 1 μl Cytotoxicity was observed in the complex powder at /ml, and high toxicity was observed at concentrations of 30 and 100 μl/ml.
이를 바탕으로 알코올 유발 세포독성 시험을 위한 적정 처리 농도를 1 μl/ml 이하의 농도로 결정하였다.Based on this, the appropriate treatment concentration for the alcohol-induced cytotoxicity test was determined to be 1 μl/ml or less.
② 대조군 시료(여명808)의 농도 결정을 위한 시료 독성 확인② Confirmation of sample toxicity to determine the concentration of the control sample (Dawn 808)
대조군으로 사용한 여명808은 0.02, 0.2, 2 μl/ml의 농도로 흰쥐에서 적출한 간세포를 일차 배양한 세포에 처리한 후 24시간 후 MTT로 확인한 결과, 세포 독성이 관찰되지 않았다. 이를 바탕으로 알코올 유발 세포독성 시험을 위한 적정 처리 농도를 결정하였다. 의뢰 복합 분말과 여명808은 유사 농도범위 내에서 독성이 없는 결과를 얻었다.Dyeing 808, which was used as a control group, was treated with hepatocytes extracted from rats at concentrations of 0.02, 0.2, and 2 μl/ml in primary cultured cells, and 24 hours later, as a result of MTT, no cytotoxicity was observed. Based on this, an appropriate treatment concentration for the alcohol-induced cytotoxicity test was determined. The requested complex powder and Dawn808 obtained non-toxic results within a similar concentration range.
③ 알코올 유발 간세포 손상 보호 효과 측정③ Measurement of the protective effect of alcohol-induced hepatocellular damage
복합 분말을 흰쥐에서 적출한 간세포를 일차 배양한 세포에 2시간 전처리한 후, 알코올(200 mM)을 처리한 후 증발을 막기 위하여 밀봉하여 24시간동안 배양한 후 세포 생존률을 MTT 분석법을 통하여 측정하였다.Hepatocytes extracted from rats were pre-treated with the complex powder for 2 hours, treated with alcohol (200 mM), sealed to prevent evaporation, and cultured for 24 hours. Cell viability was measured by MTT assay. .
도 3은 본 발명의 숙취해소용 환의 알코올 유발 간세포 손상 보호 효과 측정한 결과이다.Figure 3 is a result of measuring the alcohol-induced hepatocellular damage protective effect of the hangover relieving pill of the present invention.
여기에서 보듯이, 알코올 처리에 의하여 MTT 값의 유의적으로 감소하여, 이를 통해 알코올에 의한 세포독성이 유발됨을 확인하였다. 이러한 조건에서 복합 분말의 전처리에 의한 MTT의 수치는 농도 의존적으로 유의적으로 증가하였다. 저농도인 0.01 μl/ml에서는 다소 낮은 유의적인 차이를 보이며(p<0.01) 간세포를 보호하였지만, 농도가 높아질수록 통계적인 유의수준이 높게 알코올에 의한 간 손상을 보호하는 것을 관찰 할 수 있었다. 대조군으로 사용한 여명808은 약 40% 간 보호 효과를 나타내어, 약 30% 간 보호 효과를 나타낸 의뢰 시험물질보다 우수한 간세포 보호 효과를 보이는 것으로 관찰되었다.As shown here, it was confirmed that the MTT value was significantly decreased by the alcohol treatment, thereby induced cytotoxicity by alcohol. Under these conditions, the level of MTT by the pretreatment of the composite powder increased significantly in a concentration-dependent manner. At a low concentration of 0.01 μl/ml, it showed a rather low significant difference (p<0.01) and protected hepatocytes, but as the concentration increased, it was observed that the alcohol-induced liver damage was highly protected. Dawn808, which was used as a control, exhibited about 40% hepatoprotective effect, and it was observed that it exhibited a superior hepatocellular protective effect than the requested test substance, which exhibited about 30% hepatoprotective effect.
in vitro 상에서 복합 분말의 알코올에 대한 간세포 보호효과를 확인하였으며, 이를 토대로 in vivo 상에서 그 효과를 검증하는 연구를 진행하였다. The hepatoprotective effect of the complex powder against alcohol was confirmed in vitro, and based on this, a study was conducted to verify the effect in vivo.
(2) 숙취해소 능력 측정 (in vivo)(2) Measurement of hangover relieving ability (in vivo)
① 혈중 알코올 농도 측정 방법① How to measure blood alcohol concentration
Ethanol은 ADH (alcohol dehydrogenase)라는 간 효소에 의해 산화되어 acetaldehyde를 생성한다. 이 과정에서 NAD+라는 조효소의 도움을 받아 NADH를 생성하는데 그 생성물의 양은 흡광도 340nm에서 측정한다. 혈중 알코올 농도는 하기 수학식 2에 따라 산술하였다.Ethanol is oxidized by a liver enzyme called alcohol dehydrogenase (ADH) to form acetaldehyde. In this process, NADH is produced with the help of a coenzyme called NAD+, and the amount of the product is measured at absorbance at 340 nm. Blood alcohol concentration was calculated according to Equation 2 below.
(i) 반응 혼합물 3ml (potasium phosphate buffer pH 9 + NAD+ tablet)에 혈액 0.1ml를 혼합한다. (i) Mix 0.1ml of blood with 3ml of reaction mixture (potasium phosphate buffer pH 9 + NAD+ tablet).
(ii) 3분 동안 20℃에서 incubation(ii) incubation at 20°C for 3 min.
(iii) 340nm에서 흡광도 측정 (A1)(iii) absorbance measurement at 340 nm (A1)
(iv) ADH (alcohol dehydrogenase)를 0.05ml 넣는다.(iv) Add 0.05ml of ADH (alcohol dehydrogenase).
(v) 5분 동안 20℃에서 incubation(v) incubation at 20 °C for 5 min
(vi) 340에서 흡광도 측정 (A2) (vi) absorbance measurement at 340 (A2)
시료 경구투여 직후(0분), 알코올 처리 후 30분, 1, 2, 4 및 8시간 동안 꼬리에서 혈액을 채취하여 4,000,rpm에서 20분동안 원심분리하여 혈청을 분리하여 Ethanol colorimetric assay kit(Biovision)을 이용하여 혈중 알코올 농도(ng)를 측정하였다. Immediately after oral administration of the sample (0 minutes), after alcohol treatment, blood was collected from the tail for 30 minutes, 1, 2, 4, and 8 hours, and centrifuged at 4,000 rpm for 20 minutes to separate the serum, followed by an Ethanol colorimetric assay kit (Biovision). ) was used to measure blood alcohol concentration (ng).
그 결과, 알코올 투여군의 알코올 농도는 투여 후 1시간에서 가장 높은 수치를 보였으며, 이후 천천히 감소하는 경향을 보였으며, 환 시제품 저농도 투여군(low) 또한 알코올 투여 1시간 후에 가장 높은 수치가 관찰되었으며, 이후 급속도로 감소하는 경향을 확인할 수 있었다. 저농도 투여군에서는 알코올만 투여한 군과 비교하여 다소 혈중 알코올 농도가 낮아졌으나, 통계적인 유의성은 관찰되지 않았다. 중간농도 처리군에서는 알코올 투여 후 2시간에 가장 높은 혈중 알코올 농도를 관찰하였다. 또한 알코올 수치가 증가하는 시간이 지연되는 현상이 관찰됨에 따라 이는 곧 알코올의 혈중 흡수가 지연됨에 따라 알코올에 대한 손상이 억제될 수 있다고 볼 수 있다. 고농도(high) 투여군과 대조군으로 사용한 여명808은 알코올 투여 후 그 수치가 크게 증가하지 않으며, 또한 꾸준하게 낮은 수치를 유지하는 것을 관찰할 수 있었다.As a result, the alcohol concentration in the alcohol-administered group showed the highest value at 1 hour after administration, and then showed a tendency to decrease slowly. After that, a rapidly decreasing trend was observed. In the low concentration group, the blood alcohol concentration was slightly lower than in the alcohol-only group, but no statistical significance was observed. In the intermediate concentration treatment group, the highest blood alcohol concentration was observed 2 hours after alcohol administration. In addition, as the time for increasing the alcohol level is delayed, it can be seen that damage to alcohol can be suppressed as the absorption of alcohol into the blood is delayed. It was observed that the level of Dawn 808, which was used as a high dose group and a control group, did not increase significantly after alcohol administration, and also maintained a consistently low level.
알코올 투여 후 1시간 이후 부터는 여명 808 투여군에 비하여 고농도 환 시제품 투여에 의하여 혈중 알코올 농도가 더욱 유의적으로 낮은 경향을 확인하였다.After 1 hour after alcohol administration, it was confirmed that the blood alcohol concentration was more significantly lower than that of the Dawn 808 administration group by administration of the high-concentration pill prototype.
결과적으로, 가장 혈중 알코올 농도가 높은 시점에서 여명 808은 29.7%, 저농도는 13.6%, 중농도는 18.98%, 고농도에서는 28.86% 알코올 농도가 낮아짐을 알 수 있었다. 8시간 후 알코올 농도는 여명 808은 17.99%, 저농도는 10.98%, 중농도는 22.1%, 고농도는 18.37% 알코올 농도가 낮아짐을 알 수 있었다. As a result, it was found that at the time of the highest blood alcohol concentration, the alcohol concentration of 808 at life 808 decreased by 29.7%, at the low concentration by 13.6%, at the medium concentration by 18.98%, and at the high concentration by 28.86%. After 8 hours, it was found that the alcohol concentration decreased by 17.99% in Dawn 808, 10.98% in low concentration, 22.1% in medium concentration, and 18.37% in high concentration.
② 간 또는 혈액에서의 효소 활성 측정② Measurement of enzyme activity in liver or blood
알코올탈수소효소(alcohol dehydrogenase: ADH), 알데히드탈수소효소(aldehyde dehydrogenase : ALDH) 활성 측청용 효소원은 적출한 동물의 간 조직 또는 혈액 일정량에 4배량의 빙냉의 0.25 M 설탕 용액을 가하여 균질화한 다음 10,000×에서 20분간 원심분리하여 나온 상징액(postmitochondrial fraction, PMF) 및 미토콘드리아 분획을 사용하였다. - 알코올탈수소효소(ADH)의 활성은 Bernet & Bergermeyer의 방법(Bernet E: Methods of enzymatic analysis. Vch Pub;3rd edition pp. 1506-1509, 1983)에 따라 기질인 에탄올과 니코틴산아마이드를 첨가하여 반응시키는 동안 생성된 니코틴 아미드 아데닌 디뉴클레오티드의 함량을 파장 340nm에서 측정하였으며 활성도는 분당 단백 1 mg이 생성시킨 니코틴아미드 아데닌 디뉴클레오티드의 량을 nmole로 나타내었다. The enzyme source for alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) activity is homogenized by adding 4 times the amount of ice-cold 0.25 M sugar solution to a certain amount of liver tissue or blood of the extracted animal and then homogenizing it. The supernatant (postmitochondrial fraction, PMF) and mitochondrial fraction obtained by centrifugation at × for 20 minutes were used. - Alcohol dehydrogenase (ADH) activity was determined by adding ethanol and nicotinic acid amide as a substrate according to Bernet & Bergermeyer's method (Bernet E: Methods of enzymatic analysis. Vch Pub; 3rd edition pp. 1506-1509, 1983). The content of nicotinamide adenine dinucleotide produced during the period was measured at a wavelength of 340 nm, and the activity was expressed in nmole as the amount of nicotinamide adenine dinucleotide produced by 1 mg of protein per minute.
알데히드탈수소효소(ALDH)의 활성은 Lundquist의 방법(Bernet E: Methods of enzymatic analysis. Vch Pub; 3rd edition pp. 1, 1983)에 따라 기질인 아세트알데하이드와 니코틴산아마이드를 첨가하여 반응시키는 동안 생성된 니코틴아미드 아데닌 디뉴클레오티드의 함량을 파장 340nm에서 측정하였으며, 활성도는 분당 단백 1 mg이 생성시킨 니코틴아미드 아데닌 디뉴클레오티드의 량을 nmole로 나타내었다.The activity of aldehyde dehydrogenase (ALDH) was determined by Lundquist's method (Bernet E: Methods of enzymatic analysis. Vch Pub; 3rd edition pp. 1, 1983). Nicotine produced during reaction with the addition of acetaldehyde and nicotinic acid amide as substrates The content of amide adenine dinucleotide was measured at a wavelength of 340 nm, and the activity was expressed in nmole as the amount of nicotinamide adenine dinucleotide produced by 1 mg of protein per minute.
그 결과, 알코올탈수소효소(alcohol dehydrogenase: ADH)와 알데히드탈수소효소(aldehyde dehydrogenase : ALDH)를 측정한 결과, 알코올 투여에 의하여 효소의 활성이 감소하며, 환 시제품 중농도와 고농도 군에서는 유의적인 수준으로 효소의 활성이 유지되는 것이 관찰되었으며, ALDH 활성에서는 808보다 활성이 유의적으로 더 뛰어남을 확인하였다.As a result, as a result of measuring alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), the activity of the enzyme decreased by alcohol administration, and the enzyme activity was significantly reduced in the medium and high concentration groups of the drug test product. was observed to be maintained, and it was confirmed that the activity was significantly superior to that of 808 in ALDH activity.
ADH 활성 증가 정도는 여명(YM)은 2.26배, 저농도는 1.9배, 중농도는 2.14배, 고농도는 2.48배 활성이 증가한 것으로 관찰되었다. ALDH 활성 증가 정도는 여명(YM)은 2.27배, 저농도는 1.35배, 중농도는 2.26배, 고농도는 3.76배 활성이 증가한 것으로 관찰되었다.The degree of increase in ADH activity was observed to be 2.26-fold in lifespan (YM), 1.9-fold in low concentration, 2.14-fold in medium concentration, and 2.48-fold in high concentration. As for the degree of increase in ALDH activity, it was observed that lifespan (YM) increased by 2.27 times, at the low concentration by 1.35 times, at the middle concentration by 2.26 times, and at the high concentration by 3.76 times.
③ 환 시제품 투여로 인한 독성 평가 (동물 투여 독성)③ Toxicity evaluation due to the administration of a test product (animal administration toxicity)
도 4는 본 발명의 숙취해소용 환의 투여 후 간 중량의 변화를 나타낸 그래프이다. 실험동물에 에탄올을 투여한 결과 간의 중량이 유의적(p<0.05)으로 증가한 것을 관찰할 수 있었으며, 대조군으로 사용한 여명808에서도 유의적으로 간의 중량이 증가된 것을 알 수 있었다. Figure 4 is a graph showing the change in liver weight after administration of the hangover relieving pill of the present invention. As a result of administering ethanol to the experimental animals, it was observed that the weight of the liver increased significantly (p<0.05), and it was found that the weight of the liver was also significantly increased in Dawn808, which was used as a control.
이 결과는 여명808은 혈중 알코올 농도는 낮추는데 효과가 있었지만 간 손상에 대한 보호 효과는 미미한 것을 추론할 수 있다. 또한 in vitro에서 여명808이 알코올에 의한 간 손상을 보고하는 효과가 있었으나, 동물에 투여한 결과에서는 유의한 간 손상에 대한 보호 효과가 관찰되지 않았다. 이는 다양한 원인에 의해 발생될 수 있는 결과이며, 동물에 투여 시 투여 물질이 다양한 경로를 통해 대사되어 그 효과가 감소하였을 것이라 사료된다. From this result, it can be inferred that Dawn 808 was effective in lowering the blood alcohol level, but the protective effect on liver damage was negligible. In addition, although Dawn808 had the effect of reporting alcohol-induced liver damage in vitro, no significant protective effect against liver damage was observed in the results of administration to animals. This is a result that can be caused by a variety of causes, and it is thought that when administered to an animal, the administered substance is metabolized through various routes, and its effect is reduced.
한편, 본 발명의 숙취해소용 환의 처리군에서는 고농도 처리군에서 유의적(p<0.05)으로 간의 중량이 증가되는 것이 억제되고 있음을 관찰할 수 있었다On the other hand, in the treatment group of the hangover relief pill of the present invention, it was observed that the increase in the weight of the liver was inhibited significantly (p <0.05) in the high concentration treatment group.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As described above in detail a specific part of the present invention, for those of ordinary skill in the art, this specific description is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (3)
(S1) 울금, 헛개나무 열매, 밀크씨쓸, 갈근, 흑마늘, 인진쑥, 구기자 및 오미자 분말을 각각 준비하는 단계;
(S2) 상기 단계 (S1)에서 준비된 분말은 울금 30 내지 40 중량%, 헛개나무 열매 12 내지 16 중량%, 밀크씨쓸 20 내지 30 중량%, 갈근 10 내지 15 중량%, 흑마늘 5 내지 6 중량%, 인진쑥 3 내지 5 중량%, 구기자 3 내지 4 중량%, 및 오미자 1 내지 2 중량%를 혼합하는 단계;
(S3) 상기 단계 (S2)에서 혼합된 혼합물에 물을 가하여 반죽한 다음 롤밀로 압연하는 단계;
(S4) 상기 단계 (S3)에서 압연된 혼합물을 환 형태로 제환하는 단계; 및
(S5) 상기 단계 (S4)에서 제환된 환을 60 내지 70℃에서 7 내지 9 시간 동안 건조하는 단계.Method for producing a pill formulation for relieving hangover, comprising the following steps:
(S1) preparing each powder of turmeric, sagebrush fruit, milk seed extract, galgeun, black garlic, wormwood, goji berries and omija;
(S2) The powder prepared in step (S1) is 30 to 40% by weight of turmeric, 12 to 16% by weight of hemp fruit, 20 to 30% by weight of milk seed, 10 to 15% by weight of ground root, 5 to 6% by weight of black garlic , Injin mugwort 3 to 5% by weight, Goji berry 3 to 4% by weight, and the step of mixing 1 to 2% by weight of Schisandra;
(S3) kneading by adding water to the mixture mixed in step (S2), and then rolling with a roll mill;
(S4) ring-closing the mixture rolled in step (S3) in the form of a ring; and
(S5) drying the ring recirculated in step (S4) at 60 to 70° C. for 7 to 9 hours.
울금 분말은 PET 파우치에 울금가루를 얇게펴 두께 80mm로 한 후 가압고온살균장치에서 압력은 2000psi, 온도 121도로 20분간 살균하는 공정을 거쳐 충분히 살균되어 건조된 울금분말임을 특징으로하는 숙취해소용 환 제제의 제조방법.The method of claim 1,
Turmeric powder is a hangover relieving pill, characterized in that it is turmeric powder that has been sufficiently sterilized and dried through a process of sterilizing at a pressure of 2000 psi and a temperature of 121° C. A method for preparing the formulation.
A pill formulation for hangover relief prepared by the method of claim 1 or 2
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210047237A KR20220141377A (en) | 2021-04-12 | 2021-04-12 | A composition for relieving hangovers containing turmeric and the process for the preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210047237A KR20220141377A (en) | 2021-04-12 | 2021-04-12 | A composition for relieving hangovers containing turmeric and the process for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220141377A true KR20220141377A (en) | 2022-10-20 |
Family
ID=83805048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210047237A KR20220141377A (en) | 2021-04-12 | 2021-04-12 | A composition for relieving hangovers containing turmeric and the process for the preparation thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20220141377A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240132614A (en) | 2023-02-27 | 2024-09-04 | 정하윤 | Mixing device for alcohol and hangover cure |
-
2021
- 2021-04-12 KR KR1020210047237A patent/KR20220141377A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240132614A (en) | 2023-02-27 | 2024-09-04 | 정하윤 | Mixing device for alcohol and hangover cure |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
KR101738912B1 (en) | Composition For Anti-obesity And Diet | |
TWI500391B (en) | Composition for reliving and preventing hangover and beverage comprising composition | |
KR101930483B1 (en) | Smilax china leaf fermented with Aspergillus species and Extract of the same | |
JP2011032272A (en) | Composition for treating or preventing diabetes or diabetes complication containing compound galenical extract as active ingredient | |
KR20200120465A (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
US20110052732A1 (en) | Mineral absorption accelerator and iron deficiency anemia improver of food composition | |
KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
TWI763970B (en) | Carob fruit composition and preparation method and application thereof | |
KR101371143B1 (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
KR101394358B1 (en) | Health composition relieving alcohol hangover | |
KR20220141377A (en) | A composition for relieving hangovers containing turmeric and the process for the preparation thereof | |
KR100615039B1 (en) | Method of oriental herbal yogurt | |
Singh et al. | New dimensions in development of health-based spices and herbs fortified value added jaggery products | |
KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
EP1718167A1 (en) | Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof | |
CA2606732C (en) | Composition for preventing and treating hangover | |
KR101935861B1 (en) | Functional food composition for removing hangover and improving liver function and manufacturing method for thereof | |
KR101930026B1 (en) | manufacturing method of black garlic beverage having effect to improve liver function | |
KR20040081733A (en) | Pharmaceutical Composition for Decreasing Blood Glucose Level Containing Fermentation Product of the Extract of Banaba, Fenugreek and Bitter Mellon as a Effective Ingredient | |
KR100620093B1 (en) | Composition for preventing and treating Hangover | |
KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
KR100642801B1 (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and pear and process for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |